Roles for CD30 in the biology and treatment of CD30+ lymphoproliferative diseases

Journal of Investigative Dermatology

Volumn 122, Issue 6, 2004, Pages 1345-1347

  Granados, Suzanne ^a   Hwang, Sam T ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Bldg 10 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; IMMUNOMODULATING AGENT;

B LYMPHOCYTE; CLINICAL TRIAL; DISEASE ASSOCIATION; HODGKIN DISEASE; HUMAN; IMMUNOTHERAPY; LYMPHOMATOID PAPULOSIS; LYMPHOPROLIFERATIVE DISEASE; MYCOSIS FUNGOIDES; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; T CELL LYMPHOMA; T LYMPHOCYTE;

EID: 2942587083     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2004.22616.x     Document Type: Review

References (19)

1. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al: Primary and secondary cutaneous CD30+ lymphoproliferative disorders: A report from the Dutch cutaneous lymphoma group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95:3653-3661, 2000
2. Borchmann P, Schnell R, Fuss I, et al: Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood 100:3101-3107, 2002
3. Duckett CS, Gedrich RW, Gilfillan MC, Thompson CB: Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol 7:1535-1542, 1997
4. Duckett CS, Thompson CB: CD30-dependent degradation of TRAF2: Implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev 11:2810-2821, 1997
5. Francisco JA, Cerveny CG, Meyer DL, et al: cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458-1465, 2003
6. Horie R, Watanabe T: CD30: Expression and function in health and disease. Semin Immunol 10:457-470, 1998
7. Huhn M, Sasse S, Tur MK, et al: Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res 61:8737-8742, 2001
8. Kadin ME: The spectrum of Ki-1 + cutaneous lymphomas. Curr Probl Dermatol 19:132-143, 1990
9. Kadin ME, Cavaille-Coll MW, Gertz R, Massague J, Cheifetz S, George D: Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci USA 91:6002-6006, 1994
10. Kadin ME, Levi E, Kempf W: Progression of lymphomatoid papulosis to systemic lymphoma is associated with escape from growth inhibition by transforming growth factor-beta and CD30 ligand. Ann N Y Acad Sci 941:59-68, 2001
11. Knaus PI, Lindemann D, DeCoteau JF, et al: A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma. Mol Cell Biol 16:3480-3489, 1996
12. Krathen RA, Ward S, Duvic M: Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology 206:142-147, 2003
13. Levi E, Pfeifer WM, Kadin ME: CD30-activation-mediated growth inhibition of anaplastic large-cell lymphoma cell line: Apoptosis or cell-cycle arrest? Blood 98:1630-1632, 2001
14. Levi E, Wang Z, Petrogiannis-Haliotis T, Pfeifer WM, Kempf W, Drews R, Kadin ME: Distinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: A possible mechanism for disease progression. J Invest Dermatol 115:1034-1040, 2000
15. Macaulay WL: Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign-histologically malignant. Arch Dermatol 97:23-30, 1968
16. Mir SS, Richter BW, Duckett CS: Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 96:4307-4312, 2000
17. Mori M, Manuelli C, Pimpinelli N, et al: CD30-CD30 ligand interaction in primary cutaneous CD30+ T-cell lymphomas: A clue to the pathophysiology of clinical regression. Blood 94:3077-3083, 1999
18. Roberts AB, Wakefield LM: The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 100:8621-8623, 2003
19. Willemze R, Beljaards RC: Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 28:973-980, 1993